LARODOPA
LOE ApproachingNDAORALTABLETPriority Review
Approved
Jun 1970
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LARODOPA is an oral small-molecule tablet approved in 1970 for an unspecified indication under Roche sponsorship. The exact mechanism of action and therapeutic indication are not documented in available data, limiting clinical context.
LOE Approaching
With LOE approaching and minimal current commercial investment data, the brand team is likely in maintenance or transition planning mode, suggesting smaller team size and focus on lifecycle extension strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LARODOPA currently shows zero linked job openings, reflecting its mature LOE-approaching status. Career opportunities are limited to legacy brand management and field maintenance roles with limited growth trajectory.
Brand ManagerField Sales Representative
Worked on LARODOPA at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.